黑色素瘤辅助全身治疗的进展
Updates in adjuvant systemic therapy for melanoma.
作者信息
Kwak Minyoung, Farrow Norma E, Salama April K S, Mosca Paul J, Hanks Brent A, Slingluff Craig L, Beasley Georgia M
机构信息
Department of Surgery, University of Virginia, Charlottesville, Virginia.
Department of Surgery, Duke University, Durham, North Carolina.
出版信息
J Surg Oncol. 2019 Jan;119(2):222-231. doi: 10.1002/jso.25298. Epub 2018 Nov 27.
Abstract
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
摘要
对于III/IV期黑色素瘤手术切除后的辅助治疗，获批的辅助治疗方法迅速增加。我们回顾了辅助治疗的当前适应症，目前该适应症包括一组异质性的III期和IV期黑色素瘤患者。我们描述了全身免疫疗法、靶向免疫疗法和辅助疫苗策略的几项关键临床试验。最后，我们讨论了为个体患者选择最合适治疗方案的证据。
相似文献
1
Updates in adjuvant systemic therapy for melanoma.
J Surg Oncol. 2019 Jan;119(2):222-231. doi: 10.1002/jso.25298. Epub 2018 Nov 27.
2
Neoadjuvant Treatments for Advanced Resectable Melanoma.
J Surg Oncol. 2019 Jan;119(2):216-221. doi: 10.1002/jso.25352. Epub 2018 Dec 27.
3
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
4
Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Recent Results Cancer Res. 2000;157:178-89. doi: 10.1007/978-3-642-57151-0_15.
5
[Drug clinics. How I treat cutaneous melanoma].
Rev Med Liege. 1998 Jan;53(1):4-6.
6
Discontinuation of melanoma combination immunotherapy.
Lancet Oncol. 2017 Oct;18(10):e565. doi: 10.1016/S1470-2045(17)30668-X. Epub 2017 Sep 1.
7
Adjuvant immunotherapy for melanoma.
J Surg Oncol. 2021 Mar;123(3):789-797. doi: 10.1002/jso.26329.
8
Medical management of melanoma.
Surg Clin North Am. 2003 Apr;83(2):283-322, viii. doi: 10.1016/S0039-6109(02)00187-1.
9
Neoadjuvant therapy for resectable melanoma.
Clin Exp Metastasis. 2024 Aug;41(4):461-464. doi: 10.1007/s10585-023-10263-1. Epub 2024 Jan 28.
10
Chemotherapy in the management of advanced cutaneous malignant melanoma.
Clin Dermatol. 2013 May-Jun;31(3):290-7. doi: 10.1016/j.clindermatol.2012.08.016.
引用本文的文献
1
Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.
Ann Surg Oncol. 2025 Aug 16. doi: 10.1245/s10434-025-18063-5.
2
Completion of nodal dissection in cutaneous melanoma with metastatic sentinel nodes: Prognostic impact in a population-based cohort study.
World J Surg Oncol. 2025 Mar 29;23(1):111. doi: 10.1186/s12957-025-03762-w.
3
Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States.
Melanoma Res. 2024 Oct 1;34(5):457-464. doi: 10.1097/CMR.0000000000000990. Epub 2024 Jul 16.
4
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16.
5
Cutaneous Melanoma of the Lip: A SEER Analysis of Epidemiology and Survival Outcomes With Focus on Surgery and Other Treatment Options.
In Vivo. 2023 May-Jun;37(3):1164-1172. doi: 10.21873/invivo.13191.
6
The Evolution of the Sentinel Node Biopsy in Melanoma.
Life (Basel). 2023 Feb 10;13(2):489. doi: 10.3390/life13020489.
7
Melanoma of the Scalp and Neck: A Population-Based Analysis of Survival and Treatment Patterns.
Cancers (Basel). 2022 Dec 8;14(24):6052. doi: 10.3390/cancers14246052.
8
Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2023 Apr;30(4):2364-2374. doi: 10.1245/s10434-022-12866-6. Epub 2022 Dec 7.
9
Contrast mechanisms in pump-probe microscopy of melanin.
Opt Express. 2022 Aug 29;30(18):31852-31862. doi: 10.1364/OE.469506.
10
Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis.
Front Immunol. 2022 Aug 15;13:952220. doi: 10.3389/fimmu.2022.952220. eCollection 2022.
本文引用的文献
1
Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data.
J Cancer Res Clin Oncol. 2018 Sep;144(9):1635-1647. doi: 10.1007/s00432-018-2684-7. Epub 2018 Jun 11.
2
Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.
Ann Surg Oncol. 2018 Aug;25(8):2105-2110. doi: 10.1245/s10434-018-6513-7. Epub 2018 May 30.
3
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
4
Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21.
5
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3.
6
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
7
Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Melanoma Res. 2018 Apr;28(2):96-104. doi: 10.1097/CMR.0000000000000421.
8
Neoadjuvant systemic therapy for regionally advanced melanoma.
J Surg Oncol. 2018 May;117(6):1164-1169. doi: 10.1002/jso.24939. Epub 2017 Dec 11.
9
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eur J Cancer. 2017 Nov;86:101-105. doi: 10.1016/j.ejca.2017.09.014. Epub 2017 Sep 29.
10
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
Zotero 插件